Modulating COVID-19 disease by targeting virus and virus-induced responses through pharmaceutical and mechanical ventilation strategies: SARS-CoV-2 S-protein, ACE2 and TMPRSS2

通过药物和机械通气策略针对病毒和病毒诱导的反应来调节 COVID-19 疾病：SARS-CoV-2 S 蛋白、ACE2 和 TMPRSS2

• 批准号: nhmrc : 2003683
• 金额: $ 62.89万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/modulating-covid-19-ace2-tmprss2/1780188
• 关键词: Modulating; COVID; 19; disease; targeting

COVID-19 is a current global pandemic that is likely to be an on-going threat. We need a multipronged strategy to combat COVID-19, including therapeutic anti-virals and clinical practice management strategy. We will address both these points to define the mechanisms triggering disease, test existing drugs targeting androgens and modify the way doctors use ventilators to treat COVID-19 disease in the intensive care unit. Outcomes will have impact beyond COVID-19 for managing viral lung disease.

COVID-19是目前的全球大流行病，很可能是一个持续的威胁。我们需要多管齐下的策略来对抗COVID-19，包括治疗性抗病毒药物和临床实践管理策略。我们将解决这两个问题，以确定引发疾病的机制，测试现有的针对雄激素的药物，并修改医生在重症监护室使用抗病毒药物治疗COVID-19疾病的方式。结果将对管理病毒性肺病产生超越COVID-19的影响。